Dare Bioscience Details $6M Offering: Warrants, Fees, and Lock-Ups
DARE sits 18% above its 52-week low of $0.765 on elevated volume (19× avg).
Summary
Dare Bioscience's 8-K details its $6M offering: 4.09M shares, 8.76M warrants, 7% placement fee, and a 60-day lock-up. The raise is vital given delisting and going concern risks.
Key Events · Financing and Capital Events · DARE
-
Offering Structure Detailed
4,085,687 shares at $1.37, 293,894 pre-funded warrants at $1.3699, and 8,759,162 common warrants (Series A and B) with $1.37 exercise price.
-
Placement Agent Compensation
Ladenburg Thalmann receives 7.0% cash fee (~$420k) plus warrants for 4.0% of shares sold at $2.12 exercise price, and up to $105k expense reimbursement.
-
Lock-Up and Shareholder Approval
Company and insiders subject to 60-day lock-up; shareholder approval for warrant exercise required within 90 days, with repeated meetings if needed.
-
Registration Rights
Company must file Form S-1 for resale of common warrant shares within 30 days and use best efforts to have it effective within 60 days.
Analysis · DARE · Life Sciences
Dare Bioscience filed an 8-K detailing the terms of its $6 million registered direct offering priced at $1.37 per share. The filing adds granular specifics: 4.09 million shares, 293,894 pre-funded warrants, and 8.76 million common warrants split between Series A and B. The placement agent receives a 7% cash fee plus warrants for 4% of shares sold at $2.12. The company also agreed to a 60-day lock-up and must seek shareholder approval for warrant exercise within 90 days. Against a backdrop of a Nasdaq delisting notice and going concern doubt, this capital raise is critical for near-term survival, but the warrant overhang and fees are substantial.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1516 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DARE was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.2M. The 52-week trading range was $0.77 to $3.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.